iX Biopharma (SGX:42C) Cash-to-Debt

: 1.01 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. iX Biopharma's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.01.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, iX Biopharma could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for iX Biopharma's Cash-to-Debt or its related term are showing as below:

SGX:42C' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.01 Med: 3.33 Max: 65.79
Current: 1.01

During the past 10 years, iX Biopharma's highest Cash to Debt Ratio was 65.79. The lowest was 1.01. And the median was 3.33.

SGX:42C's Cash-to-Debt is ranked better than
51.38% of 1047 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs SGX:42C: 1.01

iX Biopharma Cash-to-Debt Historical Data

The historical data trend for iX Biopharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => 4.14 [6] => 1.45 [7] => 1.47 [8] => 3.06 [9] => 1.50 )

iX Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

4.14

1.45

1.47

3.06

1.50

iX Biopharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt																3.33	3.06	3.03	1.50	1.01

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iX Biopharma Cash-to-Debt Distribution

For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where iX Biopharma's Cash-to-Debt falls into.

iX Biopharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

iX Biopharma's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6.519	/	(3.192	+	1.146)
	=	1.50

iX Biopharma's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6.093	/	(3.095	+	2.917)
	=	1.01

iX Biopharma (SGX:42C) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

iX Biopharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of iX Biopharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

iX Biopharma (SGX:42C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994

Website

https://www.ixbiopharma.com

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma (SGX:42C) Headlines

No Headlines